| アブストラクト | BACKGROUND: Depression is common in patients with chronic viral hepatitis. We evaluated the impact of major depressive disorder (MDD) and antidepressant use on survival among patients with HBV and HCV. METHODS: We used The Health Improvement Network database, the largest medical database in the UK, to identify incident HBV (n=1401) and HCV (n=1635) in patients between 1986 and 2017. Our primary composite outcome was the development of decompensated cirrhosis or death. MDD and each class of antidepressants were assessed in multivariate Cox proportional hazards models. Models were adjusted for age, sex, and clinical comorbidities. RESULTS: The prevalence of MDD among HCV patients was higher compared with HBV patients (23.5% vs. 9.0%, p<0.001, respectively). Similarly, HCV patients were more likely to use antidepressants (59.6%) compared with HBV patients (27.1%), p>0.001. MDD was not an independent predictor for decompensated cirrhosis-free survival or mortality. However, the use of tricyclic and tetracyclic antidepressants (TCAs) was associated with poor decompensated cirrhosis-free survival in HBV and HCV cohorts (adjusted HR: 1.80, 95% CI, 1.00-3.26 and 1.56, 95% CI, 1.13-2.14, respectively). Both TCAs in the HBV cohort and selective serotonin reuptake inhibitors among the HCV cohort were associated with poor overall survival (adjusted HR: 2.18, 95% CI, 1.16-4.10; 1.48, 95% CI, 1.02-2.16, respectively). CONCLUSIONS: Although prevalent among viral hepatitis patients, MDD did not affect disease progression or survival in either HBV or HCV cohorts. TCA use was associated with poor decompensated cirrhosis-free survival. Therefore, its use should be further studied among viral hepatitis patients. |
|---|
| ジャーナル名 | Hepatology communications |
|---|
| Pubmed追加日 | 2023/2/16 |
|---|
| 投稿者 | Shaheen, Abdel Aziz; Kaplan, Gilaad G; Sharkey, Keith A; Lethebe, B Cord; Swain, Mark G |
|---|
| 組織名 | Division of Gastroenterology and Hepatology, Department of Medicine, Cumming;School of Medicine, University of Calgary, Calgary, Alberta, Canada.;Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of;Calgary, Calgary, Alberta, Canada.;Department of Physiology and Pharmacology, University of Calgary, Calgary,;Alberta, Canada.;Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary,;Calgary, Alberta, Canada. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36790342/ |
|---|
